VECT-HORUS has developed a VECTrans® technology, which combines molecules of interest to peptide-vectors that specifically target receptors involved in receptor mediated transport (RMT). This approach is presently considered as one of the most effective and safest way to by-pass the BBB.
The Company has already shown the proof of concept of its technology in animal models and one of its compounds, a vectorised neuropeptide (VH-N439,), is currently in preclinical stage. Other compounds in cancer, imaging, and neurodegenerative diseases are being developed. Some of these compounds are developed in collaboration with pharma Cies (e.g. Sanofi, Servier, Advanced Accelerator Applications).